EpiEndo Pharma announces the Appointment of Sigriður Valgeirsdóttir and Robert Helgason

EpiEndo Pharmaceuticals is a privately held biopharmaceutical company currently developing a next-generation therapeutic platform for the treatment of inflammatory disorders focused on epithelial barrier integrity as a causal factor in disease pathophysiology.

“On behalf of all of our colleagues I’d like to extend a very warm welcome to both Sigríður and Robert,” commented Prof Clive Page, OBE, Chairman of EpiEndo’s Board of Directors, “Their expertise across entrepreneurship, finance and the pharmaceutical industry is a perfect complement and brings a wealth of additional experience to the Board. I would also like to convey our gratitude for his years of service and thank EpiEndo’s Founder, Dr. Friðrik Garðarsson for his leadership, as he steps away from the Board to focus on the key executive role of Chief Innovation Officer of the Company, spearheading our strategic development. We are also immensely grateful to Prof Olafur Baldursson, whose field-leading science discoveries were a basis for EpiEndo’s inception. He will also be stepping down from his role on the Board but continues his active involvement with EpiEndo as an expert member of our Scientific Advisory Board.”

Dr. Sigríður Valgeirsdóttir is currently a governmental expert in innovation in Iceland with extensive leadership experience in the field of biotechnology and innovation. She led the development and management of the US start-up company Nimblegen Systems and was a member of the management team. Nimblegen Systems which developed and manufactured DNA microarrays for genetic studies, was acquired by the Swiss pharmaceutical company Roche in 2007 and operated under the auspices of Roche Diagnostics for the following years.

Sigríður was also a member of the Roche Diagnostics Global Operations Leadership Team from 2010 to 2013 and worked as a production manager at Roche Diagnostics and Roche Pharma in Germany from 2013 to 2017. She has a Ph.D. in molecular biology from the University of Uppsala, School of Medicine and continued with her Postdoctoral research at the Ludwig Institute for Cancer Research in Uppsala.

Mr. Robert Helgason is a finance specialist and entrepreneur with a B.Sc. in Computer Science employed as a specialist with the Treasury and Markets Operations at the Central Bank of Iceland since 2012. There, he has spearheaded work on capital control design and liberalization along with several other projects. Robert is also a founder of software startups with experience in fundraising in addition to a background in financial markets, asset management and law enforcement.

The full Board going forward now comprises Prof Clive Page, OBE, Chairman and Directors Ívar Guðjónsson and Magnús Berg Magnússon, Dr. Sigríður Valgeirsdóttir and Robert Helgason.

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders through focusing on enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Comprise of the integrity of this barrier is implicated in the progression and non-resolution of inflammation.
EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs.
EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD.

For more information, please visit www.epiendo.com

Contact
Maria Bech

CEO
E-mail: maria.bech@epiendo.com

Tel: [+44] 208 133 8664

Forward-Looking Statements

This press release may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The information in this presentation is subject to updating, completion, revision, further verification, and amendment without notice and the Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.